Codice QR

Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy

Abstract The first approved vaccines for human use against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are nanotechnology‐based. Although they are modular, rapidly produced, and can reduce disease severity, the currently available vaccines are restricted in preventing infection, str...

Descrizione completa

Salvato in:
Autori principali: Rita C. Acúrcio, Ron Kleiner, Daniella Vaskovich‐Koubi, Bárbara Carreira, Yulia Liubomirski, Carolina Palma, Adva Yeheskel, Eilam Yeini, Ana S. Viana, Vera Ferreira, Carlos Araújo, Michael Mor, Natalia T. Freund, Eran Bacharach, João Gonçalves, Mira Toister‐Achituv, Manon Fabregue, Solene Matthieu, Capucine Guerry, Ana Zarubica, Sarit Aviel‐Ronen, Helena F. Florindo, Ronit Satchi‐Fainaro
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wiley 2024-10-01
Serie:Advanced Science
Soggetti:
Dendritic cells
Intranasal
MHC class I and MHC class II peptides
Nanovaccines
PD‐1/PD‐L1 immune checkpoints
SARS‐CoV‐2
Accesso online:https://doi.org/10.1002/advs.202404159
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi